The Pharma Data

DECEMBER 2, 2020

aeruginosa bacteria, instead of killing the bacteria as an antibiotic would aim to do. The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. The new “pathoblocker” treatment aims to disarm pathogens and suppress the disease-causing properties of P.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Roots Analysis

OCTOBER 16, 2023

Further, the labor and reagent cost incurred in cloning procedures is reduced with customized cloning. Along with this, the high quality DNA clones and gene clones are customized as per the need and requirement. Genetic Synthesis: It includes in-vitro synthesis of any DNA sequence or gene without the involvement of initial template.

DNA 40

DNA Gene Protein In-Vitro 40

The Pharma Data

DECEMBER 23, 2020

The agreement includes a £500,000 upfront payment to Avacta which gives Astrea the rights to generate and develop Affimer reagents in-house for affinity separation. Astrea is a leading provider of affinity separation solutions to the pharmaceutical and biomanufacturing industries. It is a division of Gamma Biosciences.

Drugs 52

Drugs Licensing Licensing Vaccination 52

The Pharma Data

OCTOBER 14, 2020

The AOP Orphan Group manufactures 80% of its drugs in Europe and has more than 20 subsidiaries and representative offices across the whole of Europe as well as in the United Arab Emirates and Israel. The funds will be used to bring Ori’s innovative manufacturing platform to the market. million if certain project milestones are met.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52